Navigation Links
Novel cancer drug reduces neuroblastoma growth by 75 percent
Date:4/23/2009

SAN DIEGO - Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a new drug that restricts the growth of neuroblastoma, a childhood brain cancer. The pre-clinical study was presented today in the plenary session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology.

Alejandro Levy, M.D., fellow at the Children's Cancer Hospital at M. D. Anderson, presented research showing for the first time that the M. D. Anderson-developed drug, 3-BrOP, reduces tumor growth by more than 75 percent as a single agent. The study, conducted with human neuroblastoma cells transplanted into mice, showed how 3-BrOP, a glycolysis inhibitor, starved the cancer cells to death by shutting down their main energy source, glucose.

"We found that neuroblastoma cells, unlike healthy cells, are highly dependent on glycolysis for energy instead of more efficient means of energy production," said Levy. "Glycolysis is a process that breaks down sugar for energy, so by blocking that process with 3-BrOP, we are able to keep the tumors from producing energy, and this disrupts their ability to grow."

According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.

Pre-clinically, 3-BrOP has already been proven effective against other cancers including glioblastoma, colon cancer, lymphoma and acute leukemia. A Phase I clinical trial is planned to open this year for adult patients.

"As we explore alternative options to standard chemotherapy agents, we are finding drugs, like 3-BrOP, that have the potential to destroy cancer cells while leaving healthy cells unharmed," said Patrick Zweidler-McKay, M.D., Ph.D., assistant professor at the Children's Cancer Hospital and senior investigator of the study. "These drugs can often enhance the efficacy of other treatments, potentially leading to more successful combinations and better outcomes for our young patients."


'/>"/>

Contact: Lindsay Anderson
lindsay.anderson@gabbe.com
212-220-4444
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Porter Novelli Begins Work With NHLBI on COPD Awareness Effort
2. Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages
3. Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries
4. Mount Sinai researchers discover novel mechanisms that might causally link type-2 diabetes to Alzheimers disease
5. A Decision Beyond Life and Death: Novel Examines Effects of Controversial Procedure on Patients, Their Families and Doctors
6. Weight Watchers(R) Expands Licensed Food Categories with Launch of New Baked Goods, Frozen Novelty and Cheese Products to Encourage a More Sensible Lifestyle
7. Glissandra Skincare Inc. Launches Website Showcasing New and Novel Anti-Aging Skincare Products
8. AFRAID TO GO HOME, A Novel About Violence Against Women, Released By Tristan/Isolde Publishing
9. Endo Licenses Novel Pain Therapy from Grunenthal
10. Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology
11. Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 2017 , ... Support of value-based care models requires collaboration across all facets ... industry solutions, Fogo Data Centers announces the launch of the Fogo Partner Community™. , ... one in which all systems work well, work together, and work together well. ...
(Date:2/21/2017)... (PRWEB) , ... February 21, ... ... of technology-enabled clinical trial solutions, today announced the further expansion of its ... applications they can leverage as part of Bioclinica’s extensive and growing eHealth ...
(Date:2/21/2017)... ... February 21, 2017 , ... Atlanta-based Jvion, ... analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to date, received ... giants including Accenture, GE Ventures, and Software AG , will bring top ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... chronically untreated despite the medical, mental health, and financial consequences of inaction. On ... to take action if they have concerns about their hearing. , Effective treatment ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... protein espresso drinks, announced its products are now available for purchase on RonnieColemanNutrition.com, ... Drink Mix has become popular among health-conscious consumers who love coffee but are ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Liver Cirrhosis Drugs Price Analysis and Strategies ... Cirrhosis market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Liver Cirrhosis ...
(Date:2/21/2017)... and Markets has announced the addition of the "Rosacea Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Rosacea ... market? What are the unit prices and annual treatment ...
(Date:2/21/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Anthrax Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are the ... positioned in the Global Anthrax market? What are the ...
Breaking Medicine Technology: